From GlobeNewswire:

Psyence Biomedical Ltd. received two letters from Nasdaq about market value deficiencies. The Company’s securities continue to trade on Nasdaq. They have until September 9, 2024, to regain compliance. Psyence Biomedical is focused on natural psychedelics for mental health healing. The Company will actively monitor its market values and evaluate options to regain compliance with Nasdaq standards. Email [email protected] for more information. Contact Jeremy Feffer at [email protected] for investor inquiries. Learn more at www.psyencebiomed.com and on LinkedIn.



Read more at GlobeNewswire: Psyence Biomedical Ltd. Receives Nasdaq Notifications